PRESS RELEASES

Year
May 11 | 2022
RAPT Therapeutics Reports First Quarter 2022 Financial Results
May 04 | 2022
RAPT Therapeutics Expands Leadership Team with Multiple Key Hires
March 28 | 2022
RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis
March 10 | 2022
RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results
February 09 | 2022
RAPT Therapeutics to Participate in the 11th Annual SVB Leerink Healthcare Conference
January 04 | 2022
RAPT Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
November 10 | 2021
RAPT Therapeutics Reports Third Quarter 2021 Financial Results
November 09 | 2021
RAPT Therapeutics Appoints Industry Veteran Lori Lyons-Williams to its Board of Directors
November 08 | 2021
RAPT Therapeutics to Participate in Upcoming Investor Conferences
October 18 | 2021
RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b Data at the 4th Inflammatory Skin Disease Summit